To the Editor:
We read with interest the article by Takasu and colleagues investigating cardiac and renal pathologic changes in patients who died with sepsis (1). We have two comments and two questions for the authors:
The authors correctly point out that it is “difficult to know the extent of sepsis-induced myocardial depression” among their study subjects, who on average had normal ejection fractions and among whom only 13/38 (34%) required potent β-agonists (e.g., dobutamine or epinephrine). Circulatory failure from distributive shock requiring vasopressors may or may not occur in the setting of cardiac dysfunction. The study by Takasu and colleagues highlights the need for more clear definitions of “cardiac dysfunction” during sepsis.
New-onset arrhythmias [particularly atrial fibrillation (AF)] during sepsis traditionally have not been considered signs of “cardiac dysfunction.” However, epidemiologic evidence suggests that new-onset AF represents an additional “organ failure” in patients with severe sepsis. For example, hospital mortality rates of patients with new-onset AF during sepsis are similar to patients without new-onset AF, but with one additional organ failure (2). We propose that future studies include dysfunction of the cardiac electrical system as evidence of “cardiac dysfunction during sepsis,” that is, serious arrhythmias such as AF, atrial flutter, ventricular tachycardia, or ventricular fibrillation.
In regards specifically to the study by Takasu and colleagues, data from Table E4 in their online supplement shows that 6/38 (16%) of patients with sepsis had pre-existing AF and 1/38 (2.6%) developed new-onset AF. Was AF systematically ascertained by the investigators? The proportions of patients identified with AF during sepsis are much lower than previous reports.
Finally, genomic and transcriptomic variation in connexin-43 previously has been demonstrated in patients and experimental models of AF (3). Although the tissue under examination in the present study was ventricular, rather than atrial, was there overlap between the seven patients with sepsis with connexin-43 abnormalities and the seven patients who had AF during sepsis? Specifically, might AF represent an alternative mechanism for the association between sepsis and connexin-43 abnormalities? Alternatively, could connexin-43 perturbations in sepsis be a mechanism predisposing susceptible patients to AF?
Footnotes
Supported by grants K01HL116768, R21HL112672, R01HL092577, R01HL102214, from the National Heart, Lung, and Blood Institute and by grant R01AG028321 from the National Institute on Aging.
Author disclosures are available with the text of this letter at www.atsjournals.org.
References
- 1.Takasu O, Gaut JP, Watanabe E, To K, Fagley RE, Sato B, Jarman S, Efimov IR, Janks DL, Srivastava A, et al. Mechanisms of cardiac and renal dysfunction in patients dying of sepsis. Am J Respir Crit Care Med. 2013;187:509–517. doi: 10.1164/rccm.201211-1983OC. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Walkey AJ, Wiener RS, Ghobrial JM, Curtis LH, Benjamin EJ. Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis. JAMA. 2011;306:2248–2254. doi: 10.1001/jama.2011.1615. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Kato T, Iwasaki YK, Nattel S. Connexins and atrial fibrillation: filling in the gaps. Circulation. 2012;125:203–206. doi: 10.1161/CIRCULATIONAHA.111.075432. [DOI] [PubMed] [Google Scholar]